African Journal of
Pharmacy and Pharmacology

  • Abbreviation: Afr. J. Pharm. Pharmacol.
  • Language: English
  • ISSN: 1996-0816
  • DOI: 10.5897/AJPP
  • Start Year: 2007
  • Published Articles: 2199

Full Length Research Paper

Therapeutic effectiveness assessment of antiviral drugs used in chronic hepatitis treatment in three Ivorian university hospitals

Geneviève Amenan N’guessan-Irié
  • Geneviève Amenan N’guessan-Irié
  • Pharmacy Unit, University Hospital of Cocody, Côte d’Ivoire.
  • Google Scholar
Emile Allah-Kouadio
  • Emile Allah-Kouadio
  • Hepato-Gastro Enterology Unit, University Hospital of Cocody, Côte d’Ivoire.
  • Google Scholar
Christiane Ella Kogbahonon Allouka
  • Christiane Ella Kogbahonon Allouka
  • Laboratory of Pharmacology, Training and Research Unit of Pharmaceutical and Biological Sciences, Felix Houphouet-Boigny University, Côte d’Ivoire.
  • Google Scholar
Steven Driga Tchekpa Paul Kohi
  • Steven Driga Tchekpa Paul Kohi
  • Laboratory of Pharmacology, Training and Research Unit of Pharmaceutical and Biological Sciences, Felix Houphouet-Boigny University, Côte d’Ivoire.
  • Google Scholar
Bienvenu Oko Gnépéhi
  • Bienvenu Oko Gnépéhi
  • Laboratory of Pharmacology, Training and Research Unit of Pharmaceutical and Biological Sciences, Felix Houphouet-Boigny University, Côte d’Ivoire.
  • Google Scholar
Gisèle N’doua Siransy-Kouakou
  • Gisèle N’doua Siransy-Kouakou
  • Laboratory of Pharmacology, Training and Research Unit of Pharmaceutical and Biological Sciences, Felix Houphouet-Boigny University, Côte d’Ivoire.
  • Google Scholar


  •  Received: 18 October 2019
  •  Accepted: 25 November 2019
  •  Published: 31 December 2019

References

Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, Nahass R, Ghalib R, Gitlin N, Herring R, Lalezari J, Younes ZH, Pockros PJ, Di Bisceglie AM, Arora S, Subramanian GM, Zhu Y, Dvory-Sobol H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Sulkowski M, Kwo P (2014).Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. New England Journal of Medicine 370(16):1483-1493.
Crossref

 

Enel C, Loû AD, Yoman TD, Danel C, Larmarange J (2015).Viral hepatitis B and C in Côte d'Ivoire: the urgency of a revitalization of the fight. African Journal of Hepato-Gastroenterology 9(3):94-98.
Crossref

 

Feray C. (2015). L'hépatite B en Afrique: une épidémie oubliée. Humanitaire 40:68-73. URL : 

View

 

Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales F L, Craxi A (2002).Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. New England Journal of Medicine 347(13):975-982.
Crossref

 

Fried MW, Shiffman ML, Reddy RK, Smith C, Marino G, Goncales F, Hoffman J (2001).Pegylated (40kDa) interferon alfa-2a (PEGASYS®) in combination with ribavirin: Efficacy and safety results from a phase III, randomized, actively-controlled, multicenter study. Gastroenterology 120(5):55.
Crossref

 

Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Subramanian GM, Pang PS (2014). Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection. Gastroenterology 146(3):736-743.
Crossref

 

Hézode C, De Lédinghen V, Fontaine H, Zoulim F, Lebray P, Boyer N, Larrey D, Silvain C, Botta-Fridlund D, Leroy V, Bourlière M, D'alteroche L, Fouchard-Hubert I, Guyader D, Rosa I, Nguyen-khac E, Di Martino V, Carrat F, Fedchuk L, Akremi R, Bennai Y, Bronowicki JP (2015). Daclatasvir plus Sofosbuvir avec ou sans ribavirine chez les patients de génotype 3: résultats préliminaires de l'ATU de cohorte Daclatasvir. Journées de l'AFEF. Communication affichée 01.

View

 

Hutin Y, Desai S, Bulterys M (2018). Prévention de l'infection par le virus de l'hépatite B : étapes et cibles. Bulleltin de l'Organisation Mondiale de la Santé 96:443A.

 

Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, Rustgi V (2014).Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. New England Journal of Medicine 370(20):1879-1888.
Crossref

 

Lawitz E., Poordad F.F., Pang P.S., Hyland R.H., Ding X., Mo H., Symonds WT, McHutchison JG, Membreno FE (2014). Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in the treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): An open-label, randomised, phase 2 trial. Lancet 383(9916):515-523.
Crossref

 

Perrillo RP (2006). Therapy of hepatitis B - viral suppression or eradication? Hepatology 43(1):182-193. 
Crossref

 

Programme National de Lutte contre les Hépatites Virales : National Control Program of Viral Hepatitis (PNLHV). (2017). Prise en charge du cancer et des Hépatites Virales dans le cadre des Programmes « Accès Roche-Cancer du sein » et « Accès Roche-Hépatites virales ». Décision N° 1682 portant avenant du 09 octobre 2017.

 

Société Nationale Française d'Gastro-Entérologie (SNFGE). (2015). Abrégé d'hépato-gastro-entérologie et de chirurgie digestive : Partie « Connaissances », 3rd edn. Paris : Elsevier-Masson; 20p.

 

World Health Organization (‎2014)‎. Screening, care and treatment of persons with chronic hepatitis C infection: WHO guidelines 2014. 

View

 

World Health Organization (‎2016)‎. New recommendations in the updated WHO guidelines for the screening, care and treatment of persons with chronic hepatitis C infection: policy brief. World Health Organization. View